- Home
- FLYX vs ABOS Comparison
FLYX vs ABOS Comparison
Compare FLYX & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYX
- ABOS
- Stock Information
- Founded
- FLYX 2015
- ABOS 1996
- Country
- FLYX United States
- ABOS United States
- Employees
- FLYX N/A
- ABOS N/A
- Industry
- FLYX Blank Checks
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- FLYX Finance
- ABOS Health Care
- Exchange
- FLYX Nasdaq
- ABOS Nasdaq
- Market Cap
- FLYX 54.1M
- ABOS 60.6M
- IPO Year
- FLYX N/A
- ABOS 2021
- Fundamental
- Price
- FLYX $2.63
- ABOS $1.20
- Analyst Decision
- FLYX
- ABOS Strong Buy
- Analyst Count
- FLYX 0
- ABOS 4
- Target Price
- FLYX N/A
- ABOS $6.50
- AVG Volume (30 Days)
- FLYX 13.8K
- ABOS 293.8K
- Earning Date
- FLYX 08-13-2025
- ABOS 08-12-2025
- Dividend Yield
- FLYX N/A
- ABOS N/A
- EPS Growth
- FLYX N/A
- ABOS N/A
- EPS
- FLYX N/A
- ABOS N/A
- Revenue
- FLYX $335,427,000.00
- ABOS N/A
- Revenue This Year
- FLYX $28.47
- ABOS N/A
- Revenue Next Year
- FLYX $22.44
- ABOS N/A
- P/E Ratio
- FLYX N/A
- ABOS N/A
- Revenue Growth
- FLYX 5.38
- ABOS N/A
- 52 Week Low
- FLYX $1.79
- ABOS $0.86
- 52 Week High
- FLYX $5.19
- ABOS $3.60
- Technical
- Relative Strength Index (RSI)
- FLYX 42.81
- ABOS 53.50
- Support Level
- FLYX $2.77
- ABOS $1.05
- Resistance Level
- FLYX $2.80
- ABOS $1.31
- Average True Range (ATR)
- FLYX 0.23
- ABOS 0.09
- MACD
- FLYX -0.04
- ABOS 0.01
- Stochastic Oscillator
- FLYX 15.06
- ABOS 48.61
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.